HC@AIxIA: AI&Health Seminar Series (2024) - OCTOBER 21

[*apologize for multiple postings*]

Dear Madam/Sir,

This is to officially announce the NINTH seminar of the "AI & Health"
series as hosted by HC@AIxIA, i.e., the "Artificial Intelligence for
Healthcare" working group of the Italian Association for Artificial
Intelligence.

**** Save the date: 21 OCTOBER 2024. ****

We hope you will attend and participate in the discussion on the relevant
topics that will be presented and by our speakers.

*Feel free to share this with those potentially interested.*
Please find some details below, and a poster attached. All directions for
participating are available at https://aixia.it/en/gruppi/hc/.

*== Are you interested in Joining the group? ==*
Please head to https://aixia.it/en/gruppi/hc/ fo find out how. Do not
hesitate to contact us at hc-aixia@googlegroups.com for any information or
clarification.


Thank you for your interest in the AI & Health seminar series and
the HC@AIxIA working group, and see you soon!

Sincerely,
Francesco Calimeri, Mauro Dragoni, Fabio Stella
(coordinators of the HC@AIxIA working group)



*== October 2024 seminar ==*
*Link to participate: *
https://unimib.webex.com/unimib/j.php?MTID=m447969fc152aadf2062314114be484a6
(PLEASE CHECK the site https://aixia.it/en/gruppi/hc/ for any changes or
updates)

*2024 October 21 - 4:30PM CET*
*Teresa Calimeri, *Senior Staff Physician Lymphoma Unit, IRCCS San Raffale
Hospital (Milan, Italy)
 - *joint **with *Nicoletta Anzalone*, Head of the Neuroradiology Unit of
Advanced Vascular Imaging, IRCCS San *Raffale* Hospital, Milan, Italy,
and *Michela
Destito*, Department of Experimental and Clinical Medicine, University
“Magna Graecia” of Catanzaro, Catanzaro, Italy).*

*Title*:  AI in PCNSL: a diagnostic and therapeutic journey

*Abstract*: The integration of Artificial Intelligence (AI) in the field of
oncology represents one of the most significant challenges of the near
future. Recent studies indicate that radiomic features can assist
radiologists in addressing diagnostic and prognostic healthcare challenges,
potentially ushering in a new era of personalized medicine. In this
seminar, we will discuss our experience with primary central nervous system
lymphoma (PCNSL) as a case study. Initially, we will delineate the
constraints of the current diagnostic and prognostic tools. Subsequently,
we will illustrate the application of a radiomics-based machine learning
model and a deep learning (DL) approach to enhance the precision of outcome
prediction. Furthermore, we will present our ideas on the possible
application of these models in the treatment path of patients, along with
the potential integration of a composite genetic and radiomic
(radiogenomics) risk-adapted strategy. This strategy could be studied,
validated, and routinely used during PCNSL treatment. Through case studies
and recent research findings, this seminar aims to provide a comprehensive
overview of the current state and future potential of AI in PCNSL
management. *(joint work with Nicoletta Anzalone, Head of the
Neuroradiology Unit of Advanced Vascular Imaging, IRCCS San Raffale
Hospital, Milan, Italy, and Michela Destito, Department of Experimental and
Clinical Medicine, University “Magna Graecia” of Catanzaro, Catanzaro,
Italy).*

*Short Bio*: *Teresa Calimeri, MD PhD*, works in the Lymphoma Unit of the
IRCCS San Raffaele Hospital, Milan, Italy as a senior staff physician and she
has been recently identified as the clinical coordinator of the Disease
Unit Lymphoma. Dr. Calimeri’s personal research focus includes the
molecular characterization of primary and secondary CNS lymphomas along
with the applications of circulating tumor DNA (ctDNA) as a biomarker of
diagnosis, treatment response and disease prognosis. Dr. Calimeri has also
recently promoted and launched a collaboration with biomedical and
informatic engineers with the aim to apply radiomic and deep learning
approaches for the studies of lymphoid malignancies. Moreover, she is
deeply involved in the clinical management of indolent and aggressive
lymphomas. She spent part of her PhD in Molecular Oncology at The Jerome
Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute & Harvard
Medical School in Boston. In 2017, she also completed a II Level Master
course in the diagnosis and therapy of Lymphomas at the University of Udine
sponsored by the Fondazione Italiana Linfomi. She is member of both European
and International PCNSL Collaborative Group (EPCG and IPCG). She is
actively involved in the projects of the Fondazione Italiana Linfomi (FIL)
and International Extranodal Lymphoma Study Group (IELSG).

Flyer:
https://drive.google.com/open?id=1-ID-xWhRren5dUs5msqeMgv5QJOj_-92&usp=drive_fs


[image: HC@AIxIA - Seminars AI & Health 2024 - Locandina 09.png]